Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANOCRINE vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Treatment of endometriosis amenable to hormonal management,Management of fibrocystic breast disease,Hereditary angioedema (prophylaxis of attacks)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Danazol is extensively metabolized in the liver via hydroxylation and conjugation. It is a substrate of CYP3A4 and may inhibit CYP3A4, CYP2C9, and CYP2C19. The major metabolites include 2-hydroxymethylethisterone and ethisterone, which exhibit some androgenic activity.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
~80–90%, primarily to albumin and sex hormone-binding globulin (SHBG).
92% bound primarily to albumin
Vd ~0.5–1.0 L/kg; moderate tissue distribution.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Oral: ~80–100% (well absorbed).
Oral: 85% with high first-pass effect; IM: 100%
No specific guidelines; use with caution in renal impairment. Monitor fluid balance and renal function.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, use reduced dose and monitor liver function; avoid in active liver disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not recommended for use in pediatric patients due to potential for premature epiphyseal closure and other adverse effects.
Not approved for pediatric use.
No specific dosing adjustments; use lowest effective dose due to potential for increased sensitivity to androgenic effects and hepatic metabolism changes.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
None
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Risk of thromboembolic events (DVT, pulmonary embolism),Hepatotoxicity (elevated liver enzymes, jaundice, peliosis hepatis, benign hepatic adenoma),Intracranial hypertension (pseudotumor cerebri),Androgenic effects (acne, hirsutism, voice deepening, weight gain, clitoral hypertrophy),Carcinogenicity (increased risk of hepatocellular carcinoma),Use in pregnancy causes pseudothermalphroditism in female fetuses,May suppress the immune system; increased risk of infections,Can cause pancreatitis, hyperglycemia, and insulin resistance,May increase LDL and decrease HDL cholesterol,Monitor liver function, lipid profile, and signs of thrombosis
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Undiagnosed abnormal genital bleeding,Severely impaired hepatic, renal, or cardiac function,Pregnancy or breastfeeding,Porphyria,Androgen-dependent tumors (e.g., prostate carcinoma),Breast cancer in males,History of thromboembolic disease,Hypersensitivity to danazol or components
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No significant food interactions. Grapefruit juice may affect metabolism; advise caution.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Danocrine (danazol) is contraindicated in pregnancy. It is an androgen derivative and can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Risk is highest during the first trimester when genital differentiation occurs; exposure at any gestational age may result in androgenic effects.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Danazol is excreted into breast milk. The M/P ratio is unknown. Due to potential androgenic effects in the nursing infant (e.g., virilization), breastfeeding is not recommended during danocrine therapy.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Danocrine is contraindicated in pregnancy. No dose adjustment is applicable; therapy must be discontinued immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes in pregnancy are not relevant due to contraindication.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Danocrine suppresses pituitary-ovarian axis by inhibiting gonadotropin release; monitor liver function, lipid profile, and for signs of virilization. Avoid in pregnancy and porphyria.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Take with food to reduce GI upset.,Report symptoms of thromboembolism (chest pain, leg swelling) immediately.,Use non-hormonal contraception due to teratogenicity and pregnancy disruption.,May cause weight gain, edema, acne, or voice deepening; notify doctor if severe.,Avoid alcohol due to potential hepatotoxicity.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANOCRINE vs ANTAGONATE, answered by our medical review team.
DANOCRINE is a Androgen/Antigonadotropin that works by Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANOCRINE and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANOCRINE is: 100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DANOCRINE and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DANOCRINE is classified as Category C. Danocrine (danazol) is contraindicated in pregnancy. It is an androgen derivative and can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogen. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.